Hematologic Malignancies Testing Market Report 2026

The hematologic malignancies testing market size has grown rapidly in recent years. It will grow from $3.58 billion in 2025 to $4.06 billion in 2026 at a compound annual growth rate (CAGR) of 13.4%. The growth in the historic period can be attributed to increasing incidence of hematologic cancers, wider adoption of molecular diagnostics, expansion of diagnostic laboratory networks, rising use of cbc and flow cytometry, improved access to oncology testing services.

The hematologic malignancies testing market size is expected to see rapid growth in the next few years. It will grow to $6.68 billion in 2030 at a compound annual growth rate (CAGR) of 13.2%. The growth in the forecast period can be attributed to increasing demand for precision oncology diagnostics, growing integration of ai-based data interpretation, expansion of companion diagnostics, rising adoption of mrd monitoring, increasing investments in advanced diagnostic technologies. Major trends in the forecast period include increasing adoption of ngs-based diagnostic testing, rising use of flow cytometry for mrd detection, growing integration of molecular and genetic assays, expansion of personalized diagnostic profiling, enhanced focus on early and accurate subtyping.

The increasing number of cancer diagnoses is expected to drive the growth of the hematologic malignancies testing market going forward. Cancer diagnoses involve identifying the presence, type, and stage of cancer in patients through medical evaluations such as imaging, laboratory testing, and biopsies. The rise in cancer diagnoses is largely attributed to improved access to screening programs and greater public awareness, which support earlier detection. Hematologic malignancies testing supports cancer diagnosis by enabling early detection, precise classification, and continuous monitoring of blood-related cancers, thereby guiding targeted treatment decisions and improving patient outcomes. For example, according to the American Cancer Society, a US-based nonprofit organization, more than 2 million new cancer cases were diagnosed in the United States in 2024, representing a 4% increase compared to previous years. As a result, the growing number of cancer diagnoses is fueling the expansion of the hematologic malignancies testing market.

Leading companies in the hematologic malignancies testing market are concentrating on the development of advanced diagnostic approaches, such as rapid molecular profiling, to provide healthcare professionals with accurate and timely tools that improve early detection, treatment planning, and disease monitoring. Rapid molecular profiling is a diagnostic technique that examines a patient’s genetic profile to identify mutations and variations, enabling faster and more personalized treatment decisions. For instance, in November 2023, Roswell Park Comprehensive Cancer Center, a US-based comprehensive cancer center, introduced PanHeme, a next-generation gene sequencing tool designed to diagnose hematologic cancers, including leukemia, lymphoma, and multiple myeloma, with greater speed and accuracy. The test can detect mutations across hundreds of genes in less than 72 hours, significantly enhancing diagnostic precision and supporting more personalized treatment strategies.

In January 2025, Adaptive Biotechnologies Corporation, a US-based biotechnology company specializing in hematologic malignancies testing, partnered with NeoGenomics Laboratories, Inc. to advance personalized disease monitoring for blood cancer patients. Through this collaboration, the companies aim to broaden access to precise minimal residual disease monitoring by integrating the clonoSEQ test into NeoGenomics’ diagnostic offerings, thereby improving treatment decision-making and disease tracking. NeoGenomics Laboratories, Inc. is a US-based public, high-complexity clinical laboratory organization focused on cancer genetics diagnostic testing.

Major companies operating in the hematologic malignancies testing market are Abbott Laboratories, F. Hoffmann-La Roche Ltd, Siemens Healthineers AG, Becton Dickinson and Company, Bio-Rad Laboratories Inc., Agilent Technologies Inc., Illumina Inc., Thermo Fisher Scientific Inc., Danaher Corporation, Sysmex Corporation, QIAGEN N.V., PerkinElmer Inc., Adaptive Biotechnologies Corporation, Invivoscribe Inc., ArcherDx Inc., Guardant Health Inc., Sophia Genetics SA, Natera Inc., Roche Diagnostics International AG, Laboratory Corporation of America Holdings.

North America was the largest region in the hematologic malignancies testing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hematologic malignancies testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the hematologic malignancies testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the hematologic malignancies testing market by increasing costs of imported reagents, sequencing instruments, flow cytometry components, and molecular testing consumables. Diagnostic laboratories and hospitals in North America and Europe are most affected due to reliance on imported high-complexity testing equipment, while Asia-Pacific faces pricing pressure on test kits and reagents. These tariffs are raising operational costs and slowing technology upgrades. However, they are also encouraging regional manufacturing of diagnostic kits, local reagent production, and diversification of supplier bases, supporting long-term testing capacity resilience.

The hematologic malignancies testing market research report is one of a series of new reports that provides hematologic malignancies testing market statistics, including hematologic malignancies testing industry global market size, regional shares, competitors with a hematologic malignancies testing market share, detailed hematologic malignancies testing market segments, market trends and opportunities, and any further data you may need to thrive in the hematologic malignancies testing industry. This hematologic malignancies testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Hematologic malignancies testing encompasses the diagnostic and monitoring procedures used to identify, classify, and assess cancers of the blood, bone marrow, and lymphatic system. This testing precisely determines the type and subtype of malignancy, supports prognosis evaluation, informs treatment decisions, and tracks therapeutic response or disease recurrence.

The primary test types for hematologic malignancies include complete blood count (CBC), flow cytometry, molecular testing, genetic testing, and other test methods. A complete blood count (CBC) is a blood analysis that evaluates various blood components, such as red blood cells, white blood cells, hemoglobin, hematocrit, and platelets. Products are broadly classified into kits and services. The technologies used include polymerase chain reaction (PCR), next-generation sequencing (NGS), immunohistochemistry (IHC), cytogenetics, and other technologies. Key therapeutic indications include leukemia, lymphoma, multiple myeloma, myeloproliferative neoplasms, and others, and these tests are utilized by end users such as hospitals, diagnostic laboratories, academic and research institutions, and other end users.

The hematologic malignancies testing market consists of revenues earned by entities by providing biopsy testing, cytogenetic testing, and molecular testing (PCR, NGS). The market value includes the value of related goods sold by the service provider or included within the service offering. The hematologic malignancies testing market also includes sales of hematology analyzers, and bone marrow biopsy kits. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.